Stockscreener 앱 받기
22.49
4.30%
-1.01
Ultragenyx Pharmaceutical Inc 주식(RARE)의 최신 뉴스
Campbell & CO Investment Adviser LLC Grows Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Lobbying Update: $60,000 of ULTRAGENYX PHARMACEUTICAL INC. lobbying was just disclosed - Quiver Quantitative
2026-01-16 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Shareholders to Reach Out | NDAQ:RARE | Press Release - Stockhouse
Biggest stock movers Monday: DigitalBridge, Ultragenyx Pharmaceutical - MSN
Cantor Fitzgerald maintains $118 target on Ultragenyx stock - MSN
Dividend Watch: What are the future prospects of Ultragenyx Pharmaceutical Inc2025 Earnings Impact & Growth Focused Investment Plans - baoquankhu1.vn
A Look At Ultragenyx Pharmaceutical (RARE) Valuation After Upgraded 2025 Guidance And DTX401 BLA Completion - Sahm
Will Ultragenyx Pharmaceutical Inc outperform tech stocksStop Loss & Consistent Income Trade Recommendations - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Inogen (INGN), Exelixis (EXEL) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Quarterly Recap: Is Ultragenyx Pharmaceutical Inc stock ready for breakoutTrend Reversal & Daily Chart Pattern Signals - Bộ Nội Vụ
About Us - FinancialContent
Is It Time To Reconsider Ultragenyx Pharmaceutical (RARE) After A 39.1% One Year Decline? - Yahoo Finance
Ultragenyx reports preliminary 2025 revenue of $672-674 million By Investing.com - Investing.com Nigeria
A Look At Ultragenyx Pharmaceutical (RARE) Valuation After Revenue Beat And Gene Therapy Catalysts Update - Yahoo Finance
Morgan Stanley Trims Ultragenyx (RARE) PT to $50 While Betting on 2026 Biotech Recovery - Insider Monkey
Ultragenyx reports preliminary 2025 revenue of $672-674 million - Investing.com
Ultragenyx Pharmaceutical Inc. Reports Preliminary 2025 Revenue of $672 Million to $674 Million, Exceeding Guidance - Quiver Quantitative
Ultragenyx provides financial and business updates at J.P. Morgan Annual Healthcare Conference - marketscreener.com
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference - The Manila Times
Gene therapies for rare diseases move closer as Ultragenyx posts gains - Stock Titan
SG Americas Securities LLC Purchases Shares of 125,429 Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Analysts lower Ultragenyx (RARE) target but stay bullish - MSN
2026-01-11 | Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Stockholders to Inquire about Securities Investigation | NDAQ:RARE | Press Release - Stockhouse
Ultragenyx Pharmaceutical Inc. (RARE) Gets FDA CRL for UX111, Vows Quick Resubmission - MSN
Ultragenyx (RARE) Earnings Call Highlights Growth and Challenges - MSN
Can Ultragenyx Pharmaceutical Inc. (UP0) stock beat analyst consensusEntry Point & Reliable Price Breakout Alerts - Улправда
Why Ultragenyx Pharmaceutical Inc. stock is trending among retail tradersPrice Action & Low Risk Entry Point Guides - ulpravda.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - Your Wyoming Link
Can Ultragenyx Pharmaceutical Inc. stock rebound after recent weaknessMarket Movers & Fast Momentum Entry Tips - ulpravda.ru
Analysts Lower Ultragenyx (RARE) Target but Stay Bullish - Insider Monkey
Looking Into Ultragenyx Pharmaceutical Inc's Recent Short Interest - Sahm
Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
RARE ALERT: Ongoing Investigation Into Ultragenyx Pharmaceutical Inc.Contact Levi & Korsinsky - ACCESS Newswire
Ongoing Investigation into Ultragenyx Pharmaceutical Inc. (RARE): Contact Levi & Korsinsky About Potential Fraud - ACCESS Newswire
12 Stocks that Will Bounce Back According to Wall Street Analysts - Insider Monkey
How Ultragenyx Pharmaceutical Inc. stock valuations compare to rivals2025 Volatility Report & Safe Entry Trade Reports - ulpravda.ru
2026-01-08 | Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:RARE | Press Release - Stockhouse
Is Ultragenyx Pharmaceutical Inc. (UP0) stock a buy before earnings results2025 Dividend Review & AI Based Trade Execution Alerts - ulpravda.ru
Looking at the Latest Short Interest Activity for Ultragenyx Pharmaceutical Inc - Bitget
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - marketscreener.com
RBC Cuts Price Target on Ultragenyx Pharmaceutical to $35 From $72, Keeps Outperform, Speculative Risk - MarketScreener
Kyowa Kirin and Ultragenyx to proceed with US regulatory bid for burosumab - The Pharma Letter
Ultragenyx Pharmaceutical Inc. CEO to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Does Ultragenyx Pharmaceutical Inc. (UP0) stock trade below intrinsic valueCandlestick Trading Patterns & Affordable Trading Growth - ulpravda.ru
2026-01-07 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Investors to Connect | NDAQ:RARE | Press Release - Stockhouse
What is HC Wainwright's Estimate for RARE FY2025 Earnings? - MarketBeat
ATTENTION RARE Shareholders: Lost Money on Ultragenyx Pharmaceutical Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Ongoing Securities Investigation into Ultragenyx Pharmaceutical Inc. (RARE)Contact Levi & Korsinsky - ACCESS Newswire
MarketsMedicine Hat News - FinancialContent
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx ... - Bluefield Daily Telegraph
Ultragenyx Pharma stock price target lowered to $60 at H.C. Wainwright - Investing.com Nigeria
4.73%
0.92%
자본화:
|
볼륨(24시간):